

Revision date: 28-Jun-2011

Version: 1.0

Page 1 of 6

# **IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING**

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com Pfizer Ltd **Ramsgate Road** Sandwich, Kent **CT13 9NJ** United Kingdom +00 44 (0)1304 616161 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

# Material Name: BeneFIX

Trade Name:	BeneFIX
Synonyms:	Recombinant Coagulation Factor IX; nonacog alfa
Chemical Family:	Recombinant protein
Intended Use:	Pharmaceutical product used as blood clotting agent

workplace.

### 2. HAZARDS IDENTIFICATION

Appearance: Signal Word:	Powder WARNING
Statement of Hazard:	May cause allergic skin reaction.
Additional Hazard Information: Short Term:	May cause allergic reaction . Pharmaceutical blood clotting agent: may be fatal if injected or enters bloodstream
Known Clinical Effects:	This product contains protein of bovine origin. Those with known sensitivity should avoid contact. Serious allergic reactions, including anaphylaxis, have been reported. Extensive intravascular clotting and death may result if injected or allowed to enter large blood vessels.
EU Classification EU Indication of danger:	Irritant
EU Hazard Symbols: Xi	
EU Risk Phrases:	
Australian Hazard Classification (NOHSC):	R43 - May cause sensitization by skin contact. Hazardous Substance. Non-Dangerous Goods.
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not

apply in all cases. Your needs may vary depending upon the potential for exposure in your

# 2. HAZARDS IDENTIFICATION

# **3. COMPOSITION/INFORMATION ON INGREDIENTS**

Hazardous				
Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Coagulation Factor IX	9001-28-9	232-594-4	Xi, R43	250-1000 IU/vial
Sucrose	57-50-1	200-334-9	Not Listed	*
L-Histidine	71-00-1	200-745-3	Not Listed	*
Glycine	56-40-6	200-272-2	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Polysorbate 80	9005-65-6	Not Listed	Not Listed	*

#### **Additional Information:**

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

### For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES	
Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

# **5. FIRE FIGHTING MEASURES**

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.

# 6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Material Name: BeneFIX	Page 3 of 6
Revision date: 28-Jun-2011	Version: 1.0

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE	
	Minimize duct concretion and conversion. Avoid breathing duct. Avoid context with even

General Handling:	Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes,
-	skin and clothing. When handling, use appropriate personal protective equipment (see Section
	8). Wash thoroughly after handling. Releases to the environment should be avoided. Review
	and implement appropriate technical and procedural waste water and waste disposal measures
	to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA
	filtration systems or other equivalent controls.
Storage Conditions:	Store as directed by product packaging.

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Sucrose		
ACGIH Threshold Limit Value	(TWA) 10 mg/m <sup>3</sup> TWA	
Australia TWA	10 mg/m <sup>3</sup>	
Belgium OEL - TWA	Listed	
Bulgaria OEL - TWA	Listed	
Estonia OEL - TWA	Listed	
France OEL - TWA	Listed	
Ireland OEL - TWAs	Listed	
Latvia OEL - TWA	Listed	
Lithuania OEL - TWA	Listed	
OSHA - Final PELS - TWAs:	15 mg/m <sup>3</sup> total	
	5 mg/m <sup>3</sup>	
Portugal OEL - TWA	Listed	
Spain OEL - TWA	Listed	
L-Histidine		
Latvia OEL - TWA	Listed	
Glycine		
Latvia OEL - TWA	Listed	
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.	
Environmental Exposure Controls:	Refer to specific Member State legislation for requirements under Community environmental	
	legislation.	
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).	

Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk
	processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible at for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Powder	Color:	White to almost white
Molecular Formula:	Mixture	Molecular Weight:	Mixture

### **10. STABILITY AND REACTIVITY**

Chemical Stability:	Stable under normal conditions of use.
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers

# **11. TOXICOLOGICAL INFORMATION**

The information included in this section describes the potential hazards of the individual ingredients.

#### Acute Toxicity: (Species, Route, End Point, Dose)

#### Polysorbate 80 Rat Oral LD50 25

**General Information:** 

Rat Oral LD50 25 g/kg

#### Coagulation Factor IX

Mouse IP LD50 1000 ug/kg

#### Sucrose

Rat Oral LD50 29.7 g/kg

#### L-Histidine

RatOralLD 50> 15 g/kgRatPara-periostealLD 50> 2 g/kgMouseOralLD 50> 15 g/kgMouseIntravenousLD 50> 2 g/kgAcute Toxicity Comments:A greate<br/>at the bid

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose Bacterial Mutagenicity (Ames)	Salmonella Negative
Carcinogen Status:	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

# **11. TOXICOLOGICAL INFORMATION**

12. ECOLOGICAL INFORMATION		
Environmental Overview:	Environmental properties have not been investigated. Releases to the environment should be avoided.	
13. DISPOSAL CONSIDER	ATIONS	
Waste Treatment Methods:	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	

### **14. TRANSPORT INFORMATION**

#### The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# **15. REGULATORY INFORMATION**

EU Symbol: EU Indication of danger:	Xi Irritant
EU Risk Phrases:	R43 - May cause sensitization by skin contact.
EU Safety Phrases:	S24 - Avoid contact with skin. S36/37 - Wear suitable protective clothing and gloves.

**OSHA Label:** WARNING May cause allergic skin reaction.

#### **Canada - WHMIS: Classifications**

#### WHMIS hazard class: D2b toxic materials



## **15. REGULATORY INFORMATION**

Coagulation Factor IX			
EU EINECS/ELINCS List	232-594-4		
Sucrose			
Inventory - United States TSCA - Sect. 8(b)	Listed		
Australia (AICS):	Listed		
REACH - Annex IV - Exemptions from the	Present		
obligations of Register:	ricschi		
EU EINECS/ELINCS List	200-334-9		
Polysorbate 80			
Inventory - United States TSCA - Sect. 8(b)	Listed		
Australia (AICS):	Listed		
L-Histidine			
Inventory - United States TSCA - Sect. 8(b)	Listed		
Australia (AICS):	Listed		
EU EINECS/ELINCS List	200-745-3		
Objections			
Glycine			
Inventory - United States TSCA - Sect. 8(b)	Listed		
Australia (AICS):	Listed		
EU EINECS/ELINCS List	200-272-2		

### **16. OTHER INFORMATION**

#### Text of R phrases mentioned in Section 3

R43 - May cause sensitization by skin contact. **Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

Prepared by:

Product Stewardship Hazard Communications Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet